Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | NEOD001 in amyloidosis

Morie Gertz • 22 Aug 2017
EHA 2017
Amyloidosis Rare Diseases Antibodies

Morie Hertz, MD, MACO from the Mayo Clinic College of Medicine, Rochester, MN discusses the use of the novel monoclonal antibody, NEOD-001, in the treatment of amyloidosis. Several studies have been conducted to explore the effect of NEOD-001 on amyloidosis and some success has been observed. Therefore, there is a potential of the investigation to extend into the use of NEOD in the treatment of kidney amyloidosis and other forms of amyloidosis. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals